SNCA and Parkinson disease: Animal model studies of PD with GLP-1 receptor agonists (exenatide, liraglutide, and semaglutide) reported reduced dopaminergic degeneration, restored dopamine levels, improved motor function [316,400,401,402,403] and attenuated α-synuclein accumulation, reduced oxidative stress and neuroinflammation, improved MT function, stimulated autophagy, and increased glial cell line-derived neurotrophic factor expression and neurogenesis [316,403,404,405].